Biosite and Oxford Genome Sciences form colorectal cancer collaboration.Biosite Incorporated (San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. , CA) and privately-held Oxford Genome Sciences (UK) Ltd. (Oxford, England) formed a collaboration for the evaluation of protein-based disease markers for colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. . The markers could be used for the development of potential blood-based diagnostic products aimed at expanding personalized therapeutic options for colorectal cancer. In particular, these blood-based diagnostics would be designed to enable the early identification of colorectal cancer patients that have relapsed, thus enabling clinicians to select the most appropriate therapeutic option. The fecal occult blood test Fecal Occult Blood Test Definition The fecal occult blood test (FOBT) is performed as part of the routine physical examination during the examination of the rectum. and colonoscopy Colonoscopy Definition Colonoscopy is a medical procedure where a long, flexible, tubular instrument called the colonoscope is used to view the entire inner lining of the colon (large intestine) and the rectum. , a highly invasive procedure Invasive procedure may refer to:
OGeS has developed a database (the Oxford Genome Anatomy Project or OGAP OGAP Oil & Gas Accountability Project ) that integrates genomic, proteomic and clinical information derived from blood and tissue studies for a large number of diseases. Under the terms of the collaboration, OGeS will identify at least 25 proteins discovered in blood and tissue samples from relapsing colorectal cancer patients and Biosite will have the rights to develop blood-based diagnostic tests using one or more of those biomarkers. Financial terms of the agreement were not disclosed. "We are increasingly interested in studying selected areas of cancer that can benefit from rapid, effective, non-invasive diagnostic technologies," said Kim Blickenstaff, Biosite's chairman and chief executive officer. "This collaboration expands our research aimed at evaluation of diagnostic tools for relapsing colorectal cancer by providing us with access to high quality validation of potentially valuable protein biomarkers." "Relapsing disease is the major cause of suffering and death in colorectal cancer patients and there is a complete lack of clinical tools to aid physicians in the process of deciding whom to treat when and whether to treat with chemotherapy," said Christian Rohlff, OGeS' chief executive officer. "This collaboration with Biosite underpins our corporate objective of applying new strategies to the emerging field of personalized medicine  The external links in this article or section may require cleanup to comply with Wikipedia's content policies. in oncology to improve
patient outcomes."
More than 1 million Americans have colorectal cancer and more than 140,000 new cases are diagnosed each year. More than 55,000 people died from cancers of the colon/rectum in 2005. Estimated healthcare costs related to treatment for colorectal cancer in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. are more than US$8 billion. Patients with a primary diagnosis of colorectal cancer are followed up on average every three to six months for the first three years and every six months for the next two years to assess recurrence. Oxford Genome Sciences is focused on the development of personalised medicines, mainly for oncology indications. The company has developed a unique integrated platform that combines genomic, proteomic and clinical information to accelerate the discovery and validation of drug targets and biomarkers in human beings. The benefits are improved biomarkers for patient selection, drug response and efficacy monitoring, and the integration of diagnostics into drug development and product launch, thereby facilitating more accurate drug development and providing cost and time savings. OGeS' strategy is to enter into flexible strategic alliances to capture maximum value from its unique and integrated platform for the development of new therapeutics and diagnostics in the field of cancer. In parallel, the company provides target and biomarker discovery Biomarker discovery is the process by which biomarkers are discovered. It is a medical term. Many commonly used blood tests in medicine are biomarkers. The way that these tests have been found can be seen as biomarker discovery. and screening services to pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. providing OGeS with short-term revenues. OGAP holds the world's largest proprietary collection of proteins represented by the database, which contains over 1 million peptide sequences from 50 tissues and 60 disease states, mapped to approximately 15,000 genes and over 8 million single nucleotide polymorphism Noun 1. single nucleotide polymorphism - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily successful enough to recur in a and haplotypes. The database can be customised for individual partners to support and enhance their preclinical and clinical drug development activities. Biosite is a leading bio-medical company commercializing proteomics discoveries for the advancement of medical diagnosis. The company's products contribute to improvements in medical care by aiding physicians in the diagnosis of critical diseases and health conditions. Biosite's Triage triage Division of patients for priority of care, usually into three categories: those who will not survive even with treatment; those who will survive without treatment; and those whose survival depends on treatment. rapid diagnostics are used in approximately 50 percent of United States hospitals and in more than 50 international markets. Biosite Incorporated +1-858-805-2820 www.biosite.com Oxford Genome Sciences (UK) Ltd. +44-(0)-1235-861770 www.oxfordgenomesciences.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion